Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Target Cut by Wells Fargo & Company

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by stock analysts at Wells Fargo & Company from $253.00 to $220.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 29.30% from the company’s previous close.

Several other analysts also recently weighed in on the stock. Needham & Company LLC cut their price objective on shares of Alnylam Pharmaceuticals from $357.00 to $243.00 and set a “buy” rating on the stock in a research report on Thursday. Raymond James Financial cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and cut their price objective for the company from $420.00 to $315.00 in a research note on Friday. JPMorgan Chase & Co. lowered their target price on shares of Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 30th. UBS Group reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Friday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $329.81.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded down $3.86 during trading on Friday, reaching $170.14. 2,531,587 shares of the company’s stock traded hands, compared to its average volume of 1,496,795. The stock has a market capitalization of $22.77 billion, a P/E ratio of 31.68 and a beta of 0.28. Alnylam Pharmaceuticals has a 12 month low of $167.16 and a 12 month high of $479.79. The company has a 50 day moving average of $237.78 and a 200-day moving average of $287.22. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.90 EPS. On average, equities analysts expect that Alnylam Pharmaceuticals will post 6.43 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares in the company, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ALNY. Wellington Management Group LLP boosted its stake in shares of Alnylam Pharmaceuticals by 9.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after buying an additional 174,482 shares during the period. Legal & General Group Plc acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 7.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock worth $219,104,000 after acquiring an additional 50,329 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $148,128,000. Finally, Swiss National Bank increased its holdings in shares of Alnylam Pharmaceuticals by 7.9% during the first quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company’s stock worth $128,285,000 after buying an additional 28,520 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 16.7% year over year to $1.46 billion, exceeding the $1.43 billion consensus estimate. Reported EPS of $16.26 also surpassed expectations, although the result was significantly boosted by a roughly $1.9 billion tax benefit. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Management reaffirmed its fiscal 2026 outlook and anticipates $4.2 billion to $4.5 billion in TTR product sales, supporting the company’s near-term revenue base. Alnylam TTR sales outlook and TRITON-CM expansion
• Positive Sentiment: Needham maintained a “buy” rating, with a reduced $243 price target that still implies substantial upside, while Alnylam highlighted continued progress across its RNAi pipeline. Needham analyst rating
• Neutral Sentiment: Alnylam expanded the Phase 3 TRITON-CM study of nucresiran to approximately 2,250 patients while retaining an expected launch timeline around 2030. The larger trial may improve the evidence base but also raises development costs and reinforces the long wait for a potential revenue contribution. Alnylam pipeline and nucresiran update
• Negative Sentiment: Investors reacted negatively to indications that U.S. Amvuttra and Onpattro sales growth is slowing, reducing the impact of the earnings beat and raising concerns about the pace of future growth. Alnylam sales growth analysis
• Negative Sentiment: Stifel downgraded ALNY from “buy” to “hold” with a $225 target, followed by Bernstein’s downgrade from “outperform” to “market perform” with a $199 target. Although both targets remain above the recent trading level, the rating changes signal reduced conviction and added selling pressure. Stifel downgrade

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.